WBB Securities Initiates Coverage On enGene Therapeutics with Buy Rating, Announces Price Target of $21.5

WBB Securities analyst Karen Sterling initiates coverage on enGene Therapeutics (NASDAQ:ENGN) with a Buy rating and announces Price Target of $21.5.